Severe Cutaneous Adverse Reactions: A Single-Center Retrospective Study of 173 Patients in China

Zhongyi Xu*, Jie Shen1*, Yiwen Yang, Ruoyue Yuan, Leihong Flora Xiang, Chengfeng Zhang

Department of Dermatology, Huashan Hospital, Fudan University, 1Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai, China

Background: Severe cutaneous adverse reactions (SCAR) to drugs are a crucial public health issue and the use of systemic corticosteroids in SCAR has been controversial. Objective: To analyze clinical features, causative drugs, treatment, outcomes, and prognostic factors of SCAR in the case-series of 173 patients, and add more information to the debate of using systemic corticosteroids in SCAR management. Methods: A retrospective study of 173 SCAR patients diagnosed with drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) or acute generalized exanthematous pustulosis (AGEP) at a tertiary care institution in China between January 2014 and December 2017 was conducted. Results: Of 173 patients, allopurinol, carbamazepine, and antibiotics are the most frequently implicated drugs for DRESS (40.4%), SJS/TEN (26.0%), and AGEP (40.0%) respectively. Moreover, there is a strongly negative correlation between early corticosteroids use and the progression (p = 0.000) and severity (p = 0.01) of skin lesions. However, there is no association between early corticosteroids use and the mortality of SCAR (odds ratio: 1.01, 95% confidence interval: 0.95 ~ 1.08). In addition, lymphadenopathy, eosinophilia, and interval from onset to corticosteroids treatment were correlated with SCAR prognosis. Conclusion: Prompt short-course systemic corticosteroids use is associated with early-stage skin lesions remission without influencing the disease mortality. Lymphadenopathy and eosinophilia were the independent poor prognostic factors of SCAR.

Keywords- Acute generalized exanthematous pustulosis, Drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, Systemic corticosteroids treatment, Toxic epidermal necrolysis

INTRODUCTION

Severe cutaneous adverse reactions (SCAR) to drugs are among the most life-threatening conditions involving the skin, mainly encompassing drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP). DRESS is a hypersensitivity reaction, characterized by a variable combination of heterogenous clinical presentations, such as fever, lymphadenopathy, eosinophilia, facial edema, erythroderma and even internal organ involvement. SJS/TEN is known as a drug-induced hypersensitivity reaction, showing atypical target lesions and bullous lesions with acute exanthema. SJS and TEN are differentiated by the extent of epidermal detachment (SJS with body surface area [BSA] < 10%, TEN with BSA > 30%, and anything in-between called SJS-TEN overlap syndrome). AGEP is characterized by the rapid development of multiple non-follicular, sterile pustules on an ery
thematous base, mainly attributed to drugs, especially antibiotics, in the majority of cases\(^5\).

Given the severity of SCAR, numerous studies have been conducted. However, to date no specific treatment has been universally accepted. Meanwhile, information of SCAR patients in Asian population was extremely limited. In this retrospective study, we determined the reasons for administration in patients hospitalized with SCAR, the clinical pattern of reactions and the drugs causing adverse reactions in the biggest department of dermatology in China. Most notably, we aimed to examine the role of systemic corticosteroids in SCAR treatment and explore the potential prognostic factors of SCAR.

**MATERIALS AND METHODS**

**Patient selection**

A retrospective review of electronic medical records was performed for all patients admitted to Department of Dermatology, Huashan Hospital as DRESS, SJS/TEN, and AGEP between January 2014 and December 2017. Inclusion criteria for this study required that patients met the diagnostic guidelines set by the European Registry of Severe Cutaneous Adverse Reactions (RegiSCAR)\(^6\) for DRESS and SJS/TEN or the modified European Study of Severe Cutaneous Adverse Reactions (EuroSCAR) described by Sidoroff et al.\(^7\) for AGEP. No patients were lost to follow-up in this retrospective study. Informed consent was obtained from all patients to use their electronic medical data. The study protocol was approved by the Ethical Committee of Huashan Hospital (IRB no. KY2019-316).

**Assessment of drug causality**

The drugs responsible for SCAR were defined as previously described\(^6\)\(^7\). The evaluation of drug causality was decided by a group of experienced dermatologists. In brief, if a drug was used continuously for more than three months, withdrawn for more than 14 days, or with a latent period less than three days, it would not be considered as the culprit drug for DRESS or SJS/TEN\(^6\). However, latent period for AGEP could be less than three days (typically within 48 hours or 24 hours for antibiotics)\(^8\). The “latent period” referred to the period from drug initiation to symptom onset. Moreover, previous use without a drug eruption history decreased suspicion, whereas an earlier reaction prioritized the drug. Hereafter, the remaining suspected drugs were re-evaluated based on the literature review. For cases with several suspected drugs remained, those with high notoriety were firstly considered (listed in Table 1) and those with low notoriety were marked as ‘possible’ (not listed in Table 1). Moreover, the sensitizing

| Table 1. Causative drugs of SCAR |
|----------------------------------|
| **Associated drug** | **Case (%)** |

**DRESS**

| Associated drug | Case (%) |
|-----------------|----------|
| Allopurinol     | 23 (40.4) |
| Sulfasalazine   | 8 (14.0)  |
| Phenobarbital   | 4 (7.0)   |
| Carbamazepine   | 4 (7.0)   |
| Mexiletine      | 3 (5.3)   |
| Antibiotics (antifungals) | 4 (7.0) |
| Cephalosporin (cefprozil, cefoxitin) | 2 |
| Amoxicillin     | 1        |
| Flucnazolide    | 1        |
| TCM (radix isatidis, propolis, herbs) | 3 (5.3) |
| Indomethacin    | 2 (3.5)  |
| Other drugs*    | 4 (7.0)  |

**SJS/TEN**

| Antibiotics | Case (%) |
|-------------|----------|
| Carbamazepine | 25 (26.0) |
| Antibiotics  | 15 (15.6) |
| Cephalosporin (cefotaxime, cefmetazole, cefotiam, cefprozil, cefepime) | 6 |
| Levofloxacine | 4 |
| Metronidazole | 2 |
| Amoxicillin  | 1        |
| Clarithromycin | 1 |
| Erythromycin | 1        |
| Glicazolamide | 5 (5.2) |
| Compound paracetamol and amantadine | 4 (4.2) |
| Edaravone    | 2 (2.0)  |
| Phenytoin    | 2 (2.0)  |
| Sulfasalazine | 2 (2.0)  |
| Valaciclovir | 2 (2.0)  |
| Valproate    | 2 (2.0)  |
| Other drugs† | 10 (10.4) |

**AGEP**

| Antibiotics | Case (%) |
|-------------|----------|
| Antibiotics | 8 (40.0) |
| Cephalosporin (cefaclor, cefotiam, cefepime) | 3 |
| Clindamycin | 2 |
| Azithromycin | 1 |
| Levofloxacine | 1 |
| Iseamicin   | 1        |
| TCM (notoginseng triterpenes, radix isatidis, Cordyceps sinensis) | 6 (30.0) |

**NSAIDS**

| Paracetamol | 1 |
| Meloxicam   | 1 |
| Urea C 14   | 1 (5.0) |

SCAR: severe cutaneous adverse reactions, DRESS: drug reaction with eosinophilia and systemic symptoms, TCM: traditional Chinese medicine, SJS: Stevens-Johnson syndrome, TEN: toxic epidermal necrolysis, AGEP: acute generalized exanthematous pustulosis, NSAIDS: nonsteroidal anti-inflammatory drugs. *Compound paracetamol and amantadine, flunarizine, oxcarbazepine, and phenytoin. †Amlodipine, dabigatran, fentanyl, oosotide, paracetamol, phenobarbital, pyrazinamide, rabeprazole, tenus anti-toxin, and tropicamide.
properties of different drugs were also taken into account.

Assessment of SCAR outcomes

Clinical information with regards to demographic data, comorbidities, latency, and duration from onset to maximum BSA or BSA detachment (maximum BSA detachment for SJS/TEN and maximum BSA skin lesion involvement for DRESS and AGEP), maximum BSA or BSA detachment, time from onset to pharmacotherapy, co-administration of corticosteroids and intravenous immunoglobulin (IVIG) was recorded and analyzed. Outcomes analyzed for pharmacotherapy were progression of disease (defined as duration from the index day to maximum BSA or BSA detachment), severity of disease (maximum BSA or BSA detachment) and mortality. The 25th and 75th percentile of the time length of the lesions withdrawal by 50% were calculated, and prognosis were defined as good when 50% of the lesions withdrew less than seven days.

Statistical analysis

Linear regression analysis was applied to explore the association between the time from onset to corticosteroids treatment and progression of disease (duration from the index day to maximum BSA or BSA detachment) or severity of disease (maximum BSA or BSA detachment), while mortality analysis was based on logistic regression. Linear regression models were adjusted for age, sex, and disease classification (SJS/TEN, DRESS or AGEP) and co-administration of IVIG in order to take into account the confounding factors. In terms of prognostic factor analysis of SCAR, chi-squared test and one-way ANOVA were applied for univariate analysis. Then, the variables significantly associated with prognosis of SCAR in univariate analysis and the variables of great clinical concerns were further included in Cox regression analysis and enter selection was applied. The categorical variables were coded. The threshold for significance was set at \( p \)-value \(<0.05\). All statistical analyses were performed using IBM SPSS Statistics ver. 21.0 software (IBM Corp., Armonk, NY, USA).

RESULTS

Demographics

As shown in Table 2, 173 SCAR patients were studied in this study. SJS/TEN was the most prevalent SCAR observed (55.5%, 96 cases), followed by DRESS (32.9%, 57 cases) and AGEP (11.6%, 20 cases). Males were predominant (1.48:1) in DRESS and females were predominant (0.54:1) in AGEP, whereas the number of males and females were similar for SJS/TEN. The mean period from drug initiation to symptom onset is 27.4 days for DRESS, 14.3 days for SJS/TEN, and 6.2 days for AGEP. The most common underlying diseases justifying the use of drugs were hyperuricemia or gout in DRESS, infection in SJS/TEN and AGEP.

Table 2. Demographics

|                  | DRESS (n = 57) | SJS/TEN (n = 96) | AGEP (n = 20) |
|------------------|----------------|-----------------|--------------|
| Sex ratio (male/female) | 1.48 (34/23)   | 1 (48/48)       | 0.54 (7/13)  |
| Age (yr)         | 50.5 (32.3–66) | 51.5 (31.8–65)  | 36 (31.3–55) |
| Latent period (d)*| 27.4±4.3       | 14.3±2.1        | 6.2±2.4      |
| Underlying disease |                |                 |              |
| Hyperuricemia/gout | 23 (40.4)      | 11 (11.5)       | -            |
| Infection†       | 8 (14.0)       | 27 (28.1)       | 9 (45.0)     |
| Inflammatory disease† | 8 (14.0)     | 2 (2.1)         | 2 (10.0)     |
| Seizure/paralysis/spasm | 7 (12.3)          | 15 (15.6)       | -            |
| Pain§           | 5 (8.8)        | 14 (14.6)       | 3 (15.0)     |
| Others           | 5 (8.8)        | 19 (19.8)       | 3 (15.0)     |

Values are presented as ratio, median (interquartile range), mean±standard deviation, or number (%). DRESS: drug reaction with eosinophilia and systemic symptoms, SJS: Stevens-Johnson syndrome, TEN: toxic epidermal necrolysis, AGEP: acute generalized exanthematous pustulosis, -: not applicable. *The period from drug initiation to symptom onset. †DRESS: respiratory infection (5 cases), vaginitis (1 case), nasosinusitis (1 case), gastroenteritis (1 case). SJS/TEN: respiratory infection (8 cases), eye infection (5 cases), vaginitis (3 cases), duodenal ulcer with Helicobacter pylori infection (2 cases), sepsis (2 cases), cervicitis (2 cases), skin infection (2 cases), gastroenteritis (1 case), tuberculosis (1 case). AGEP: respiratory infection (2 cases), cholecystitis (1 case), gastroenteritis (2 cases), otitis (2 cases), nasosinusitis (1 case), urocytis (1 case). §DRESS: ankylosing spondylitis (4 cases), osteoarthrite (1 case), Crohn’s disease (1 case), rheumatic arthritis (1 case), ulcerative colitis (1 case). SJS/TEN: ulcerative colitis (2 cases). AGEP: rheumatic arthritis (1 case), periarthritis humeroscapularis (1 case). ‡DRESS: neuralgia (2 case), meningeal pain (1 case), post-surgery pain (1 case), pharyngalgia (1 case). SJS/TEN: postherpetic neuralgia (5 cases), trigeminal neuralgia (3 cases), headache (3 cases), pharyngalgia (1 case), neuralgia (1 case), and post-surgery pain (1 case). AGEP: pharyngalgia (3 cases).
Table 3. Clinical characteristics

| Characteristic                                     | DRESS (n = 57)         | SJS/TEN (n = 96)         | AGEP (n = 20)          |
|---------------------------------------------------|------------------------|-------------------------|------------------------|
| n                                                 | 95% CI                 | n                       | 95% CI                 | n                       | 95% CI                 |
| Fever ≥ 38.5°C                                     | 43 (63 ± 85)           | 80 (75 ± 89)            | 10 (30 ± 70)           |                         |
| Lymphadenopathy                                    | 36 (50 ± 74)           | 22 (16 ± 32)            | 2 (3 ± 30)             |                         |
| Atypical lymphocytes                               | 11 (11 ± 31)           | 2 (0 ± 7)               | 1 (1 ± 24)             |                         |
| Leucocytosis                                       | 36 (50 ± 74)           | 27 (20 ± 38)            | 15 (53 ± 89)           |                         |
| Leucocytopenia                                     | 0 -                    | 22 (16 ± 32)            | 0 -                    |                         |
| Neutrophilia                                       | 27 (35 ± 60)           | 32 (25 ± 43)            | 16 (58 ± 92)           |                         |
| Lymphocytosis                                      | 0 -                    |                         | 0 -                    |                         |
| Monocytosis                                        | 20 (24 ± 48)           | 15 (10 ± 24)            | 5 (11 ± 47)            |                         |
| Leucocytosis (>10,000 U/L)                         | 5 (4 ± 19)             | 7 (4 ± 14)              | 0 -                    |                         |
| Leucocytopenia (<4,000 U/L)                        | 0 -                    | 6 (3 ± 13)              | 1 (1 ± 24)             |                         |
| Eosinophilia                                       | 44 (65 ± 86)           | 9 (5 ± 17)              | 1 (1 ± 24)             |                         |
| Grade 1                                            | 11 (11 ± 31)           | 7 (4 ± 14)              | 1 (1 ± 24)             |                         |
| Grade 2                                            | 33 (45 ± 70)           | 2 (0 ± 7)               | 0 -                    |                         |
| Extent of rash >50%                                | 56 (91 ± 100)          | 95 (94 ± 100)           | 17 (84 ± 95)           |                         |
| Suggestive rash                                    | 52 (81 ± 96)           | 87 (83 ± 95)            | 20 (84 ± 100)          |                         |
| Facial edema                                       | 49 (75 ± 93)           | 46 (38 ± 58)            | 5 (25 ± 47)            |                         |
| Monomorphic maculopapular                          | 16 (28 ± 41)           | 2 (0 ± 7)               | 0 -                    |                         |
| Polymorphous maculopapular                         | 40 (57 ± 80)           | 94 (93 ± 99)            | 20 (84 ± 100)          |                         |
| Urticarial                                         | 0 -                    |                         | 0 -                    |                         |
| Exfoliative                                        | 18 (21 ± 44)           | 88 (84 ± 96)            | 1 (1 ± 24)             |                         |
| Lichenoid                                          | 1 (0 ± 9)              | 0 -                     | 1 (1 ± 24)             |                         |
| Pustules                                           | 0 -                    | 1 (0 ± 6)               | 20 (84 ± 100)          |                         |
| Purpura                                            | 15 (26 ± 39)           | 30 (23 ± 41)            | 4 (20 ± 41)            |                         |
| Infiltrated plaques                                | 54 (86 ± 98)           | 41 (33 ± 53)            | 13 (54 ± 82)           |                         |
| Blisters                                           | 9 (9 ± 27)             | 74 (68 ± 84)            | 3 (15 ± 36)            |                         |
| Target-like lesions                                | 4 (7 ± 17)             | 41 (33 ± 53)            | 4 (20 ± 41)            |                         |
| Eczema-like lesions                                | 11 (11 ± 31)           | 3 (1 ± 9)               | 3 (15 ± 36)            |                         |
| Mucosal involvement                                | 17 (30 ± 43)           | 90 (86 ± 97)            | 0 -                    |                         |
| Mouth/throat/lips                                  | 12 (21 ± 33)           | 87 (83 ± 95)            | 0 -                    |                         |
| Eyes                                               | 3 (5 ± 14)             | 53 (45 ± 65)            | 0 -                    |                         |
| Genitalia                                         | 9 (9 ± 27)             | 69 (72 ± 80)            | 0 -                    |                         |
| Other                                              | 1 (0 ± 9)              | 22 (15 ± 31)            | 0 -                    |                         |
| Internal organ involvement*                        | 56 (91 ± 100)          | 85 (81 ± 93)            | 6 (15 ± 52)            |                         |
| 1 Organ involved                                   | 16 (28 ± 41)           | 36 (28 ± 47)            | 5 (21 ± 47)            |                         |
| 2 Organs involved                                  | 30 (53 ± 65)           | 31 (24 ± 42)            | 1 (1 ± 24)             |                         |
| >2 Organs involved                                 | 10 (18 ± 29)           | 18 (12 ± 28)            | 0 -                    |                         |
| Liver                                              | 54 (86 ± 98)           | 69 (72 ± 80)            | 6 (15 ± 52)            |                         |
| Kidney                                             | 26 (43 ± 58)           | 53 (45 ± 65)            | 1 (5 ± 24)             |                         |
| Lung                                               | 12 (21 ± 33)           | 14 (9 ± 23)             | 0 -                    |                         |
| Muscle/heart                                       | 9 (9 ± 27)             | 18 (12 ± 28)            | 1 (5 ± 24)             |                         |
| Pancreas                                           | 1 (2 ± 9)              | 5 (2 ± 12)              | 0 -                    |                         |
| Other                                              | 0 -                    | 1 (0 ± 6)               | 0 -                    |                         |

Leucocytosis >10,000 U/L, Leucocytopenia <4,000 U/L, Neutrophilia >7,000 U/L, Lymphocytosis >4,000 U/L, Monocytosis >1,000 U/L, Thrombocytopenia >400,000 U/L, Thrombocytopenia <100,000 U/L, Eosinophilia Grade 1: 700 ~1,499 U/L, Eosinophilia Grade 2: >1,500 U/L. DRESS: drug reaction with eosinophilia and systemic symptoms, SJS: Stevens-Johnson syndrome, TEN: toxic epidermal necrolysis, AGEP: acute generalized exanthematous pustulosis, -: stands for not applicable. *Liver: elevation of liver enzymes (twice the normal value), kidney: elevation of creatinine (twice the normal value) or the occurrence of proteinuria or hematuria, lung: inflammation or interstitial change on X-ray or computerized tomography (CT), muscle: elevation of creatine kinase (CK), heart: elevation of CK-muscle/brain or myoglobin, spleen: splenomegaly reported on ultrasound or CT, pancreas: elevation of serum/uric amylase or lipase, or pancreatic edema reported on CT.
Clinical characteristics

The clinical characteristics of the 173 SCAR patients were summarized in Table 3. Fever $\geq 38.5^\circ\text{C}$ was documented in 75% of DRESS patients, 83% of SJS/TEN patients and 50% of AGEP patients. Lymphadenopathy was observed in 63% and 23% of DRESS and SJS/TEN patients respectively. Notably, 19% DRESS patients, 2% SJS/TEN patients and 5% AGEP patients showed peripheral atypical lymphocytes. Leucocytosis was found in 63% of DRESS, 28% of SJS/TEN and 75% of AGEP patients. Leucocytopenia was infrequent, with only 23% in SJS/TEN. Neutrophilia was found in 47% of DRESS, 33% of SJS/TEN and 80% of AGEP patients. Monocytosis was prevalent in DRESS patients (35%) but not in SJS/TEN (16%) and AGEP (25%). Thrombocytopenia was rare, with only 6% in SJS/TEN. Eosinophilia, defined as an absolute eosinophil count $\geq 700$ U/L, was present in 77% of DRESS patients. While in SJS/TEN, only 9% of patients had an absolute eosinophil count $\geq 700$ U/L. All patients experienced an acute skin eruption. 91% of DRESS and SJS/TEN patients, and all of the AGEP patients had suggestive rash. The criteria for suggestive rash was facial edema or exfoliative dermatitis in DRESS, edematous erythema, target-like lesions, mucosal involvement, flaccid vesicles, and exfoliation in SJS/TEN, and sterile nonfollicular pustules in AGEP. The rash was a monomorphic papular in 28% of DRESS patients and only 2% of SJS/TEN patients, while in all other cases it was polymorphous, including variable combinations of other lesions. For example, DRESS patients usually had infiltrated plaques (95%), exfoliation (32%), purpura (26%), eczema-like lesions (19%), and blisters (16%). Whereas, SJS/TEN patients usually had exfoliation (92%), blisters (77%), target-like lesions (43%), and purpura (31%). Facial edema was observed in 86% of DRESS patients, 48% of SJS/TEN patients and 25% of AGEP patients. Mucosal involvement was recorded in 30% of DRESS patients and 94% of SJS/TEN patients. Most popular were oral lesions (21% of DRESS patients and 90% of SJS/TEN patients). In terms of systemic involvement, most frequently the reaction affected the liver (95% of DRESS patients, 72% of SJS/TEN patients, and 30% of AGEP patients), followed by kidney (46% of DRESS patients, 55% of SJS/TEN patients, and 5% of AGEP patients) and lung (21% of DRESS patients and 15% of SJS/TEN patients).

Causative drugs

In this study, two DRESS patients (3.5%), eight SJS/TEN patients (8.3%), and three AGEP patients (15.0%) were not exposed to any medication according to the criteria of culprit drugs in RegiSCAR® or modified EuroSCAR for AGEP®. As for other SCAR cases, the summary of drug causality was presented in Table 1. In addition, we categorized all SCAR cases by causative drugs into three groups: allopurinol group, carbamazepine group, and other causative drugs group. Univariate analysis of the outcome measures showed difference in the severity of SCAR ($p=0.031$) but no difference in the progression of SCAR among three causative drugs groups. Further two-two comparisons also showed that the difference between allopurinol group and carbamazepine group ($p=0.039$) and the difference between carbamazepine group and other causative drugs group were statistically significant ($p=0.010$). However, when stratified by disease types, causative drugs showed difference only in the severity of SJS/TEN, whereas no differences in the severity of DRESS or AGEP.

Treatment

In our observational study, 56 DRESS patients (98.2%), 96 SJS/TEN patients (100.0%), and 20 AGEP patients (100.0%) received systemic corticosteroids. Intravenous methylprednisolone was given at 1~1.5 mg/kg/d. Once the progression of the disease was halted, which manifested as no new lesions, Nikolsky sign turning negative, exudation improved, re-epithelialization and laboratory test results being stable, the dose of corticosteroids was tapered promptly. Meanwhile, 43 DRESS patients (75.4%), 88 SJS/TEN patients (91.6%), and four AGEP patients (20.0%) received treatment with IVIG. IVIG was administered at 0.4 g/kg/d for over 5 days. Univariate analysis of the outcome measures showed that early use of systemic corticosteroids was significantly and negatively related to the progression of SCAR ($p=0.001$) and the severity of SCAR ($p=0.000$). Further multivariate analysis also indicated the negative linear association of early use of systemic corticosteroids and the progression ($p=0.000$) and the severity of SCAR ($p=0.01$) (Table 4). Duration from onset to maximum BSA or BSA detachment will be 0.858-day longer when the initiation of systemic corticosteroids was delayed for 1 day (Table 4). It means later systemic corticosteroids use might prolong the duration of active stage SCAR, and it would take more time for SCAR patients to reach stable stage (no new lesions). Moreover, one-day delay of the systemic corticosteroids use would increase 19.2% of maximum BSA or BSA detachment (Table 4). In contrast, IVIG treatment did not statistically affect the primary outcomes of both the disease progression and severity. Among all 173 SCAR patients, none of them died during their stay in hospital, and only two DRESS patients (3.5%), four SJS/TEN patients (4.2%) and no AGEP patient...
Table 4. Linear regression of SCAR progression and severity (complete case analysis: 57 DRESS, 96 SJS/TEN, and 20 AGEP)

|                                      | Unadjusted linear regression | Adjusted linear regression |
|--------------------------------------|------------------------------|----------------------------|
|                                      | Standardized coefficients β | p-value                    | Standardized coefficients β | p-value |
| Duration from onset to maximum BSA or BSA detachment |                             |                            |                             |         |
| Time from onset to corticosteroids treatment | 0.857 | 0.000 | 0.858 | 0.000 |
| Classification                         |                             |                            |                             |         |
| AGEP                                  | 0                            |                             | 0                           |         |
| DRESS                                 | 0.285 | 0.02  | 0.022 | 0.758 |
| SJS/TEN                               | 0.158 | 0.195 | 0.04  | 0.599 |
| Age (yr, linear)                      | −0.002 | 0.952 | 0.011 | 0.790 |
| Sex                                   | 0.019 | 0.802 | −0.069 | 0.885 |
| IVIG                                  | 0.166 | 0.029 | 0.052 | 0.274 |
| Maximum BSA or BSA detachment         |                             |                            |                             |         |
| Time from onset to corticosteroids treatment | 0.0244 | 0.001 | 0.192 | 0.010 |
| Classification                         |                             |                            |                             |         |
| AGEP                                  | 0                            |                             | 0                           |         |
| DRESS                                 | 0.14  | 0.232 | 0.099 | 0.442 |
| SJS/TEN                               | −0.212 | 0.07  | −0.225 | 0.100 |
| Age (yr, linear)                      | −0.108 | 0.156 | −0.097 | 0.180 |
| Sex                                   | −0.015 | 0.846 | −0.055 | 0.445 |
| IVIG                                  | −0.047 | 0.542 | 0.026 | 0.759 |

Maximum BSA for AGEP and DRESS, and maximum BSA detachment for SJS/TEN. SCAR: severe cutaneous adverse reactions, DRESS: drug reaction with eosinophilia and systemic symptoms, SJS: Stevens-Johnson syndrome, TEN: toxic epidermal necrolysis, AGEP: acute generalized exanthematous pustulosis, BSA: body surface area, IVIG: intravenous immunoglobulin.

died in the first three months after discharge. Both two DRESS patients died of lung infection. Three SJS/TEN patients died of multiple organ dysfunction syndrome, and one SJS/TEN patients died of lactic acidosis. For mortality analysis, no statistical difference was revealed between early and delayed systemic corticosteroids use (odds ratio [OR]: 1.01, 95% confidence interval [CI]: 0.95~1.08) (Table 5).

Prognostic factors of SCAR

Following risk factors were included in the regression model to analyze their associations with SCAR: disease type, age, sex, lymphadenopathy, eosinophilia, mucosal involvement, internal organ involvement, interval from onset to standard treatment with adequate corticosteroids, combination therapy with IVIG, and causative drugs (Table 6). Multivariate analysis showed disease type (p=0.035), lymphadenopathy (p=0.001), eosinophilia (p=0.019) and interval from onset to standard treatment with adequate corticosteroids (p=0.000) were the independent risk factors for the prognosis of SCAR. Patients with lymphadenopathy had longer time for 50% lesions' withdrawal than those with no lymphadenopathy (OR: 2.356, 95% CI: 1.433~3.875). Moreover, when we categorized eosinophilia into three groups: moderate (<700), high (700~1,500) and higher (>1,500), high levels of eosinophilia proved to be a poor prognosis factor of SCAR, with 2-fold higher risks of longer lesions’ withdrawal time (high, OR: 1.58 (0.26~9.49)).
Table 6. Prognostic factors of SCAR (complete case analysis: 57 DRESS, 96 SJS/TEN, and 20 AGEP)

| Covariate                                | Univariate          |                          |                      |                      |
|------------------------------------------|---------------------|--------------------------|----------------------|----------------------|
|                                          | p-value  | B      | Exp (B) (95% CI) | p-value  |
| Disease type                             | 0.001    | 0.717  | 2.048 (0.674~6.224) | 0.035    |
| SJS/TEN                                  | 0.001    | -0.683 | 0.505 (0.228~1.116) | 0.206    |
| AGEP                                     | 0.046    | 0.297  | 1.346 (0.919~1.971) | 0.127    |
| Sex                                      | 0.21     | 0.975  | 2.882 (0.980~8.746) | 0.075    |
| Age (yr)                                 | 0        | 1.000  | 0.000 (0.998~1.001) | 0.206    |
| Lymphadenopathy                          | 0.025    | 0.857  | 2.356 (1.433~3.875) | 0.001    |
| <700                                     | 0.021    | 0.718  | 2.048 (0.674~6.224) | 0.035    |
| 700~1,500                                | 0.01     | 0.997  | 2.709 (1.283~5.721) | 0.009    |
| >1,500                                   | 0.127    | 0.757  | 2.133 (1.059~4.296) | 0.034    |
| Mucosal involvement                      | 0.001    | 0.207  | 1.231 (0.635~2.385) | 0.539    |
| Internal organ involvement               | 0.187    | 0.409  | 1.531 (0.868~2.693) | 0.145    |
| No organ involved                        | 0.37     | 0.185  | 1.183 (0.776~1.795) | 0.293    |
| 1 Organ involved                         | 0.171    | 0.491  | 1.633 (0.732~3.644) | 0.213    |
| 2 Organ involved                         | 0.058    | 0.154  | 1.166 (0.535~2.540) | 0.699    |
| 3 And more organs involved               | 0.046    | 0.193  | 1.213 (0.523~2.812) | 0.653    |
| Interval from onset to corticosteroids treatment | -0.038  | -0.36  | 0.698 (0.401~1.214) | 0.203    |
| IVIG                                     | 0        | -0.36  | 0.698 (0.401~1.214) | 0.203    |
| Causative drugs                          | 0.37     | 0.185  | 1.183 (0.776~1.795) | 0.293    |
| Allopurinol                              | 0.161    | 0.706  | 0.391 (1.274)      | 0.248    |
| Carbamazepine                            | 0.35     | 0.677  | 0.412 (1.113)      | 0.124    |
| Others                                   | 0.37     | 0.185  | 1.183 (0.776~1.795) | 0.293    |

SCAR: severe cutaneous adverse reactions, DRESS: drug reaction with eosinophilia and systemic symptoms, SJS: Stevens-Johnson syndrome, TEN: toxic epidermal necrolysis, AGEP: acute generalized exanthematous pustulosis, IVIG: intravenous immunoglobulin.

2.709, 95% CI: 1.283~5.721; higher, OR: 2.133, 95% CI: 1.059~4.296, compared with moderate eosinophilia level. Furthermore, interval from onset to standard treatment with adequate corticosteroids was proved to be a protective factor for the prognosis of SCAR (OR: 0.963, 95% CI: 0.943~0.983). However, mucosal involvement, internal organ involvement, co-treatment with IVIG and SCAR causative drug types were not independent prognostic factors for SCAR.

**DISCUSSION**

Previous studies showed conflicting results about the incidence of SCAR in different genders. In our study, DRESS occurred more common in male than female. It might be due to the fact that 40.4% DRESS cases had underlying hyperuricemia or gout, which is much more prevalent in men as well11. Whereas in SJS/TEN and AGEP, infection (28.1% for SJS/TEN and 45.0% for AGEP) was the most common underlying disease, which was consistent with previous study12.

According to our data, internal organ involvement (98%), facial edema (86%), eosinophilia (77%), high fever (75%), leukocytosis (63%), and lymphadenopathy (63%) were characteristic for DRESS. As for SJS/TEN, the main features next to the ubiquitous exanthema were mucosal involvement (94%), internal organ involvement (89%), fever (83%), and neutrophilia (33%). As for AGEP, the main features were pustules (100%), neutrophilia (80%), leukocytosis (75%), and fever (50%). Notably, our findings revealed that 46 SJS/TEN patients (48%) had facial edema, which was quite different from the traditional concept that facial edema was the warning signal for DRESS and rarely occurred in other SCAR6. We considered that diffuse erythema on face in combination with mucosal involvement like conjunctivae or lips13 could manifest as facial edema in severe SJS/TEN cases. Additionally, 17 DRESS patients (30%) had mucosal involvement, which was similar as previous reported3. Nine SJS/TEN patients (9%) had increased peripheral eosinophil counts, which highlighted that eosinophilia could occur in SCAR other than DRESS5. Some studies even reported that eosinophilia was associated with poor SCAR outcomes15-17. Higher percentage of lymphadenopathy in DRESS (63%) than other SCAR...
was similar to previous studies, which would be explained by the potential activation of virus infections, such as Epstein-Barr virus, cytomegalovirus or human herpesvirus 6 in DRESS. Six AGEP (30%) had internal organ involvement, which was similar to previous studies that AGEP-specific hepatitis, nephritis or pneumonia were rare but sometimes occurred. Thus, systemic investigations were recommended for all SCAR types. Over the past few decades, important progress has been made in understanding the pathogenesis of SJS/TEN, especially the role of human leukocyte antigen (HLA) alleles. Antiepileptic agents (phenobarbital, carbamazepine, phenytoin, and lamotrigine), minocycline, allopurinol, dapsone, and sulphonamides are the most frequently reported causative drugs of DRESS. In our study, the most common culprit drug for DRESS was allopurinol. HLA-B *58:01 has been reported to be associated with allopurinol-induced SCAR. As for carbamazepine, the leading causative drug for SJS/TEN in our study, HLA-B *15:02 was responsible for carbamazepine-induced SJS/TEN, and HLA-A *31:01 showed a stronger correlation with carbamazepine-induced DRESS. Antibiotics were the leading cause of AGEP in our findings, which was also in agreement with previous reports. However, further studies are required with regard to the limited number of AGEP patients in our study. Notably, 5.3% DRESS, 8.3% SJS/TEN, and 30.0% AGEP cases were caused by traditional Chinese medicine (TCM) use. The associated TCMs were radix isatidis, propolis, scolopendra, salvianolate, sophora flavescens, berberine, paraquat, Leonurus artemisia, bezoar, berberine, notoginseng triterpenes, Cordyceps sinensis, and Platycarya strobilacea. Among those listed, only paquiatu has been reported to cause TEN, and propolis has been reported to cause fixed drug eruption. All other TCMs were newly reported. Considering the popular application of TCM treatment in Asian cultures, connection between TCM and SCAR needs to be further clarified. In our study, there were still a small number of SCAR cases with no culprit drugs, which was in accordance with previous studies that SCAR could attribute to exposures other than medications, such as infection, foods or transplantation. Systemic corticosteroids have long been regarded as the mainstay treatment for SCAR. However, it is still controversial how much benefit patients would get from this treatment. Some case series have concluded that the use of systemic steroids were beneficial in reducing morbidity and mortality, whereas others suggesting minimal or no benefit in terms of outcome. Some earlier observational studies even indicated an increased mortality and a higher frequency of complications for TEN patients treated with systemic steroids. Here, we reveal that early steroids therapy could alleviate the severity and progression of SCAR without influencing the mortality rate. These results suggest that early short-course steroids use is helpful in the initial phase management of SCAR at least in a modern well-equipped tertiary care hospital. Since more than 98.2% SCAR cases received systemic steroids, we could not demonstrate the difference of outcomes with and without systemic steroids use. Further studies with different therapy are required to answer this question. SCAs are associated with significant morbidity, mortality, and socioeconomic costs. Predicting outcomes for each specific SCAR patient at an early stage would be extremely helpful for physicians to formulate appropriate treatment strategy. However, very few clinical researches have focused on the prognostic factors of SCAR. According to our results, lymphadenopathy and eosinophilia were associated with a poor outcome. The role of eosinophilia in the outcomes of SCAR has been reported before, while lymphadenopathy as a poor prognostic factor for SCAR was reported for the first time. This can be explained by the potential activation of virus infections, such as Epstein-Barr virus, cytomegalovirus or human herpesvirus 6.

Limitations of the study included the retrospective design and a predominance of Asian population. Since most SCAR patients in our study had received systemic corticosteroids in combination with IVIG, further case-control studies with larger sample size are required for more detailed research. In addition, there have been no universal rules that could determine the causative drug of SCAR with certainty, and the rule used in this study is imperfect as well. Moreover, the long-term follow-up of SCAR patients post-discharge was lacking. However, due to the fact that the ultimate prospective blinded study needed to provide a more definitive answer to the questions about steroid use in SCAR management is extremely difficult to do, our study is of significance in guiding clinical practice. In conclusion, allopurinol, carbamazepine, and antibiotics were the most frequent implicated drugs for DRESS, SJS/TEN, and AGEP respectively. Hyperuricemia or gout was the most frequent cause of administration in DRESS, and infection was that in SJS/TEN and AGEP. Selection and prescription of those drugs should be more cautiously. Additionally, early initiation of steroids might help prevent the progression of skin lesions and decrease the severity of skin lesions or skin detachment, but had no correlation with mortality. Lymphadenopathy and eosinophilia were the independent poor prognostic factors of SCAR. For SCAR patients with lymphadenopathy and eosi-
noffilia, physicians may consider taking a more aggressive therapeutic approach.

ACKNOWLEDGMENT

This work was supported by grants from Natural Science Foundation of China (No. 81573064 and 81472901) and Shanghai Sailing Program (No. 19YF1404800). We thank Prof. Xiaojun Luo for her critical reading, and thank Dr. Shengen Chen and Xiaojin Wu for their excellent technical assistance.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

ORCID

Zhongyi Xu, https://orcid.org/0000-0001-8158-0825
Jie Shen, https://orcid.org/0000-0003-2504-4491
Yiwen Yang, https://orcid.org/0000-0003-0145-7283
Ruoyue Yuan, https://orcid.org/0000-0001-6970-8611
Leihong Flora Xiang, https://orcid.org/0000-0003-2080-0550
Chengfeng Zhang, https://orcid.org/0000-0002-1302-5667

REFERENCES

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
2. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-257.
3. Kardaun SH, Sidoroff A, Valelye-Anallone L, Haley S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007;156:609-611.
4. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia Q, Schröder W, Roujeau JC, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138:1019-1024.
5. Szatkowski J, Schwartz RA. Acute generalized exanthematosus pustulosis (AGEP): a review and update. J Am Acad Dermatol 2015;73:843-848.
6. Kardaun SH, Sekula P, Valelye-Anallone L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013;169:1071-1080.
7. Sidoroff A, Haley S, Bavincck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)–a clinical reaction pattern. J Cutan Pathol 2001;28:113-119.
8. Sidoroff A, Dunant A, Viboud C, Haley S, Bavincck JN, Naldi L, et al. Risk factors for acute generalized exanthematosus pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007;157:989-996.
9. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol 2013;69:187.e1-16; quiz 203-204.
10. Speeckaert MM, Speeckaert R, Lambert J, Brochez L. Acute generalized exanthematosus pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol 2010;20:425-433.
11. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63:3136-3141.
12. Okamoto-Uchida Y, Nakamura R, Sai K, Imatoth T, Matsunaga K, Aihara M, et al. Effect of infectious diseases on the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis. Biol Pharm Bull 2017;40:1576-1580.
13. Dodik-Gad RP, Chung WH, Valelye-Anallone L, Shear NH. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol 2015;16:475-493.
14. Duong TA, Valelye-Anallone L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet 2017;390:1996-2011.
15. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol 2013;68:709.e1-9; quiz 718-720.
16. Lee JY, Lee SY, Hahm JE, Ha JW, Kim CW, Kim SS. Clinical features of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a study of 25 patients in Korea. Int J Dermatol 2017;56:944-951.
17. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010;146:1373-1379.
18. Barbaud A, Dupin N, Roujeau JC. [DRESS and viruses]. Ann Dermatol Venereol 2018;145:120-124, French.
19. Ishida T, Kano Y, Mizukawa Y, Shiohara T. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome. Allergy 2014;69:798-805.
20. Ropars N, Darrieux L, Tisseau L, Safa G. Acute generalized exanthematosus pustulosis associated with primary Epstein-Barr virus infection. JAAD Case Rep 2014;1:9-11.
21. Hotz C, Valelye-Anallone L, Haddad C, Bouvrresse S, Ortonne N, Duong TA, et al. Systemic involvement of acute generalized exanthematosus pustulosis: a retrospective study on 58 patients. Br J Dermatol 2013;169:1223-1232.
22. Choi MJ, Kim HS, Park HJ, Park CJ, Lee JD, Lee JY, et al. Clinicopathologic manifestations of 36 korean patients with acute generalized exanthematosus pustulosis: a case series and review of the literature. Ann Dermatol 2010;22:163-169.
23. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose
K, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010;51:2461-2465.
24. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-1143.
25. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995;155:2285-2290.
26. Wongkitisophon P, Chanprapaph K, Rattanakaemakorn P, Vachiramon V. Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms. Acta Derm Venereol 2012;92:200-205.
27. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005;102:4134-4139.
28. Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012;92:757-765.
29. Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014;55:496-506.
30. Sassi EH, Beau-Salinas F, Jonville-Béra AP, Lorette G, Autret-Leca E. [Drugs associated with acute generalized exanthematous pustulosis]. Ann Dermatol Venereol 2003;130:612-618. French.
31. Xu W, Wang L, Wang Q, Li XH, Hu D, Li C, et al. Paraquat poisoning followed by toxic epidermal necrolysis: a report of two cases and published work review. Dermatology 2015;231:209-212.
32. Ramien ML, Pratt MD. Fixed drug eruption to ingested propolis. Dermatitis 2012;23:173-175.
33. Heng YK, Lee HY, Roujeau JC. Epidermal necrosis: 60 years of errors and advances. Br J Dermatol 2015;173:1250-1254.
34. Kardaun SH, Jonkmann MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007;87:144-148.
35. Ang CC, Wang YS, Yoosuff EL, Tay YK. Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol 2010;63:219-227.
36. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008;58:33-40.
37. Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrarie-Allanore L, et al. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol 2012;167:555-562.
38. Funck-Brentano E, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, et al. Therapeutic management of DRESS: a retrospective study of 38 cases. J Am Acad Dermatol 2015;72:246-252.
39. Ginsburg CM. Stevens-Johnson syndrome in children. Pediatr Infect Dis 1982;1:155-158.
40. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-512.
41. Kelemen JJ 3rd, Cioffi WG, McManus WF, Mason AD Jr, Pruitt BA Jr. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180:273-278.
42. Wei CH, Chung-Yee Hui R, Chang CJ, Ho HC, Yang CH, Lin YJ, et al. Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol 2011;21:930-937.
43. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-153.